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Abstract: In October 2015 we published the paper ‘Measurement of HbA1c in multicentre diabetes trials – should
blood samples be tested locally or sent to a central laboratory: an agreement analysis’. Chatterjee and Pradhan have
submitted a letter to the editor asking critical questions regarding the methods we used.
We offer this letter in response.
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Main text
We thank Chatterjee and Pradhan for their letter re-
garding our paper in Trials. 2016; 17-517. We agree
with their sentiment that local HbA1c measurement
cannot be implemented at the expense of clinically
unacceptable disparities between centralised and local-
ised measurements despite its greater cost efficiency.
We hope that the following provides the additional
information that will aid their assessment of our
results.
Time-lag
In their letter, Chatterjee and Pradhan draw attention
to Fig. 3 of our paper, and notice that within centres
the distribution of differences is centred on 0 (suggest-
ing that there are no centre-specific systematic biases
present). We would argue that this does not imply that
the same relationship would necessarily be true for
time-lag. Figure 3 displayed results by site; however,
within a site the time lag may vary. We have produced
boxplots to show the distribution of differences by
time-lag and a scatterplot as requested. This demon-
strates an absence of a linear relationship between
time-lag and discrepancy. They also indicate that in
practice time-lag can be an important factor for high
glucose values. As part of the underlying assumptions
of the Bland-Altman method we investigated heterosce-
dasticity (see the Verification of assumptions section
within the ‘Results’ section of our paper), i.e. we did not
observe any increase in discrepancy with higher glyco-
sylated haemoglobin (HbA1c).
Of the 590 measurements analysed for agreement,
for 79 (13.4%) the date of measurement at the central
laboratory was not recorded. These 79 are indicated
with ‘M’ on Fig. 1 and excluded from Fig. 2 (scatter-
plot). For the remaining 511, in only 8 (1.5%)
measurements was there a time-lag of more than
7 days. The Pearson’s correlation between time-lag
and difference in measurements (local minus central
HbA1c) was found to be −0.02. This was statistically
not different from 0 (p = 0.48). This means that there
is no evidence of a straight-line relationship (linear
correlation) between time-lag and agreement. (See
Figs. 1 and 2)
HbA1c measurement methodology
We specify in our paper that in almost all cases, both
local and central, HbA1c was measured via immuno-
assay using portable machines. Local measurements
were normally taken at outpatient clinics – but the
technical method of measurement employed was not* Correspondence: bna@liverpool.ac.uk
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recorded. At the time of analysis, we contacted all
sites to establish what the local methodology was.
Table 1 gives details of what the sites’ responses were.
We can give further detail here to say that the same
portable machine was used at Alder Hey for outpatient
clinics as at the central laboratory (based at Alder Hey).
At this centre therefore, the methodology was identical.
Differences were still incurred despite using the same
machine with a short time-lag and removing the cour-
ier and post-transfer issues (see Fig. 3).
Whether central laboratory results should be used in
preference to local results is an issue that needs to be
considered at the design stage of any study. We hope
that the information presented will enable greater clarity
Fig. 1 Boxplots showing the distribution of differences between local and central measurements by time-lag in days: between blood samples
being taken and analysis at the central laboratory. M: measurements where the date of laboratory measurement was not recorded
Fig. 2 Scatterplot showing the distribution of the magnitude of differences between local and central measurements by time-lag in days: between
blood samples being taken and analysis at the central laboratory
Arch et al. Trials  (2017) 18:242 Page 2 of 4
in decisions made. However, any decision needs to be
born against the size of the effect that is to be detected
and the potential size of discrepancies. This study dem-
onstrates that despite quality control placed on local ma-
chines such discrepancies do occur. It should also be
emphasised that this study took place in the UK and the
climate and transport conditions elsewhere may deter-
mine whether local measurements are preferable.
Acknowledgements
None to add.
Funding
SCIPI was funded by the Health Technology Assessment (HTA) programme of
the National Institute for Health Research (NIHR). Project reference: 08/14/39.
Availability of data and materials
The data for these analyses are available on request from the lead author.
Authors' contributions
All authors read and approved the final manuscript. BA carried out the
analysis and wrote the statistical methods, results and much of the
discussion section, and drafted the manuscript. JB wrote part of the
background section and reviewed the manuscript. AM helped with data
issues and reviewed the manuscript. JWG reviewed the manuscript. PN
contributed the biochemistry methodology and reviewed the manuscript.
CG raised the original question and led the statistical team contributing to
the statistical analysis plan, analyses, and manuscript.
Authors' information
BA is a statistician at the CTRC2; JB is a consultant endocrinologist, and the
SCIPI1 CI; AM is the SCIPI1 trial statistician at the CTRC2; JWG is a professor in
paediatric endocrinology at the University of Cardiff, and a co-investigator
and PI for SCIPI1; PN is a consultant biochemist at Alder Hey Children’s Hos-
pital; CG is deputy-HoD of Biostatistics at the University of Liverpool and
deputy director of the CTRC2.
1SCIPI: Randomised controlled trial of continuous subcutaneous insulin
infusion compared to multiple daily injection regimens in children and
young people at diagnosis of type I diabetes mellitus.
2CTRC: Clinical Trials Research Centre, University of Liverpool.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Fig. 3 Scatterplot of discrepancies in measurements by time-lag at Alder Hey Hospital (location of central laboratory)
Table 1 Local HbA1c measurement methodology, as reported
by sites
Centre Code Local measurement methodology
1 Main method: DCA machine; 2 other possibilities: local
laboratory or Hh9210 premier analyser machine by A
Menarini Diagnostics
2 Machine in clinic
3 Diabetes team have their own machine
4 Method during follow-up: DCA machine in clinic calibrated
daily with local laboratory
5 Machine on the ward
6 DCA Vantage in the Diabetes Centre. QC managed by
pathology department in the hospital
7 Siemens DCA Vantage machine in clinic
8 Alfinion machine in outpatients
9 Portable DCA machine
10 Machine in clinic
11 Method during follow-up: DCA 2000 machine in clinic
12 Machine in clinic
13 Main method: local laboratory (till April 2015); then new
analyser machine
14 Technician from local laboratory brings a machine to the
clinic
15 DCA analyser for majority of follow-up appointments
QC quality control
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